Previous 10 | Next 10 |
ANI Pharmaceuticals (NASDAQ:ANIP) is trading ~3.7% higher in the pre-market on below-average volume after announcing the FDA approval of its Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg. ANI’s newly approved Rifabutin capsules are a generic version of t...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (“FDA”) approval for the Abbreviated New Drug Application for Rifabutin Capsules USP, 150 mg. ANI...
Product is now available exclusively through Anovo specialty pharmacy Product is stable at room temperature while Carbaglu® requires refrigeration Eton Cares patient support program will offer $0 co-pays to commercial insurance patients DEER PARK, Ill., Dec. 20, 2021 ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following the initial devastation of the coronavirus pandemic, the U.S. economy has so far engineered an impressive recovery. Although not every metric is perfectly aligned, we can say this much: the early (and understandab...
The Nasdaq Biotechnology Index will have a new look on December 20, before the market opens when 129 securities will be added and 21 securities will be deleted as part of the annual reconstitution. Notable additions to the index: Viatris (NASDAQ:VTRS), NovoCure (NASDAQ:NVCR), Anavex Life Scie...
-- Combined company creates generics growth engine with technical capabilities to bring complex, high-value products to market in efficient and cost effect manner -- -- Proven track record with largest number of Competitive Generic Therapy (CGT) approvals -- -- Deep pipeline wit...
ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as f...
The Federal Trade Commission has granted clearance for ANI Pharma's (NASDAQ:ANIP) acquisition of Novitium Pharmaceuticals. As a condition of the acquisition, the companies are divesting two generic products. ANI says that divestiture will have no impact on its business. ANI expects the merger...
-- Divestiture Required by FTC of Two Generic Products Immaterial to Company’s Business -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Federal Trade Commission (the FTC) has accepted the proposed consent order in connect...
ANI Pharmaceuticals (ANIP -5.4%), which agreed to acquire Novitium Pharma for $163.5M, will need to divest two generic products as a condition of the merger, per an FTC order. Development rights to sulfamethoxazole-trimethoprim oral suspension and manufacture of oral dexamethasone are in...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....